Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511862
Status:
COMPLETED
Last Update Posted:
2021-05-13
First Post:
2007-08-02
Brief Title:
TheraSphere for the Treatment of Liver Metastases
Sponsor:
Boston Scientific Corporation
Organization:
Boston Scientific Corporation
Study Overview
Official Title:
TheraSphere for the Treatment of Liver Metastases An Open Label Trial of TheraSphere in Patients With Liver Metastases From Primary Colorectal Cancer Neuroendocrine Cancer or Non-colorectalNon-neuroendocrine Cancer
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate Liver Progression Free Survival PFS and safety of TheraSphere treatment at doses of 120 Gy 1 10 in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be treated or is progressing following treatment with systemic or other liver-directed therapies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None